We are live on ! Find out more
HVC

Healthcare Value Capital Portfolio holdings

AUM $50.7M
1-Year Est. Return 24.72%
This Fund
S&P 500
This Quarter Est. Return
-4.66%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$55.7M
AUM Growth
-$2.81M
Cap. Flow
-$4.01M
Cap. Flow %
-7.2%
Top 10 Hldgs %
88.36%
Holding
23
New
4
Increased
4
Reduced
–
Closed
6

Top Buys

Rank Stock Value
1
ASRT
Assertio
ASRT
+$2.22M
2
BIS icon
ProShares UltraShort NASDAQ Biotechnology
BIS
+$681K
3
LAB icon
Standard BioTools
LAB
+$405K

Top Sells

Rank Stock Value
1
AMRI
Albany Molecular Research Inc
AMRI
+$4.24M
2
AORT icon
Artivion
AORT
+$2.69M
3
ZGNX
Zogenix, Inc.
ZGNX
+$346K
4
FCSC
Fibrocell Science Inc.
FCSC
+$39.3K

Sector Composition

Rank Sector Weight
1 Healthcare 65.94%
2 Miscellaneous 34.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PFE icon
1
Pfizer
PFE
$160B
$8.4M 15.09%
263,500
– –
NVLN
2
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$7.67M 13.79%
831,440
– –
ASRT
3
DELISTED
Assertio
ASRT
$5.91M 10.61%
9,167
+3,334
+57% +$2.22M
GILD icon
4
Gilead Sciences
GILD
$185B
$5.31M 9.54%
75,000
– –
BIS icon
5
CALL
ProShares UltraShort NASDAQ Biotechnology
BIS
$1.77M
$4.85M 8.72%
25,000
+21,875
+700% +$4.77M
GILD icon
6
CALL
Gilead Sciences
GILD
$185B
$4.25M 7.63%
60,000
– –
AORT icon
7
PUT
Artivion
AORT
$1.3B
$3.99M 7.17%
+200,000
New +$3.58M
AGN
8
DELISTED
Allergan plc
AGN
$3.65M 6.55%
15,000
– –
VIXY icon
9
CALL
ProShares VIX Short-Term Futures ETF
VIXY
$212M
$2.66M 4.78%
+781
New +$3.01M
TEVA icon
10
Teva Pharmaceuticals
TEVA
$43.8B
$2.49M 4.48%
75,000
– –
AMRN
11
Amarin Corp
AMRN
$299M
$1.81M 3.26%
22,500
– –
LAB icon
12
Standard BioTools
LAB
$253M
$1.46M 2.62%
360,500
+85,500
+31% +$405K
ASRT
13
CALL
DELISTED
Assertio
ASRT
$1.07M 1.93%
1,667
– –
IMMU
14
CALL
DELISTED
Immunomedics Inc
IMMU
$883K 1.59%
100,000
– –
BIS icon
15
ProShares UltraShort NASDAQ Biotechnology
BIS
$1.77M
$606K 1.09%
+3,125
New +$681K
LAB icon
16
CALL
Standard BioTools
LAB
$253M
$606K 1.09%
150,000
+100,000
+200% +$474K
FCSC
17
CALL
DELISTED
Fibrocell Science Inc.
FCSC
$40K 0.07%
+2,000
New +$24.7K
AORT icon
18
Artivion
AORT
$1.3B
– –
-150,000
Closed -$2.69M
SPY icon
19
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$827B
– –
-25,000
Closed -$5.89M
FCSC
20
DELISTED
Fibrocell Science Inc.
FCSC
– –
-3,185
Closed -$39.3K
IPXL
21
CALL
DELISTED
Impax Laboratories, Inc.
IPXL
– –
-200,000
Closed -$2.53M
AMRI
22
DELISTED
Albany Molecular Research Inc
AMRI
– –
-302,400
Closed -$4.24M
ZGNX
23
DELISTED
Zogenix, Inc.
ZGNX
– –
-31,850
Closed -$346K

Similar funds

C
Castlelake Minneapolis, Minnesota $48.5M AUM 87.77% 1-Year Est. Return
CC
Cedar Capital Barrington, Illinois $54.9M AUM 33.3% 1-Year Est. Return
FCOI
FirstMark Capital OF II New York $44.1M AUM 18.15% 1-Year Est. Return
FCOI
FirstMark Capital OF I New York $43.1M AUM 6.31% 1-Year Est. Return
BI
BCBSM Inc Eagan, Minnesota $42.4M AUM 0.4% 1-Year Est. Return
KC
Kelso & Company New York $42.3M AUM
SCIM
Spring Creek Investment Management Philadelphia, Pennsylvania $42.3M AUM 31.86% 1-Year Est. Return
MCP
Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return

Healthcare Value Capital's Q2 2017 Portfolio in Review

As of Q2 2017, Healthcare Value Capital held 23 positions worth $55.7M, down 4.8% from $58.5M the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Healthcare Value Capital withdrew a net $4.01M in Q2 2017, closing 6 positions. Its most notable exit was Albany Molecular Research Inc, an estimated $4.24M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, down from 74% a quarter earlier, followed by Miscellaneous.

Against the trend, Healthcare Value Capital opened a new position in ProShares UltraShort NASDAQ Biotechnology worth $606K.

  • Healthcare Value Capital's largest Q2 2017 buy was ProShares UltraShort NASDAQ Biotechnology: 3,125 shares worth $606K.
  • Healthcare Value Capital added most to Assertio in Q2 2017, an estimated $2.22M increase.
  • Healthcare Value Capital fully exited Albany Molecular Research Inc in Q2 2017, selling an estimated $4.24M.
  • Healthcare Value Capital's ten largest holdings make up 88% of its $55.7M portfolio in Q2 2017.
  • Healthcare Value Capital opened 4 new positions and closed 6 in Q2 2017.
  • Healthcare Value Capital's portfolio value fell 4.8% quarter-over-quarter to $55.7M.

Based on Healthcare Value Capital's 13F filing for Q2 2017, filed 10 Aug 2017.